Johnson & Johnson (JNJ) : Partners Capital Investment Group scooped up 747 additional shares in Johnson & Johnson during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 11, 2016. The investment management firm now holds a total of 149,743 shares of Johnson & Johnson which is valued at $17 Million.Johnson & Johnson makes up approximately 4.91% of Partners Capital Investment Group’s portfolio.
Other Hedge Funds, Including , Troy Asset Management Ltd boosted its stake in JNJ in the latest quarter, The investment management firm added 7,000 additional shares and now holds a total of 136,886 shares of Johnson & Johnson which is valued at $15.5 Million. Johnson & Johnson makes up approx 0.85% of Troy Asset Management Ltd’s portfolio.Amica Mutual Insurance Co reduced its stake in JNJ by selling 18,076 shares or 10.49% in the most recent quarter. The Hedge Fund company now holds 154,191 shares of JNJ which is valued at $17.4 Million. Johnson & Johnson makes up approx 1.65% of Amica Mutual Insurance Co’s portfolio. Arkansas Financial Group added JNJ to its portfolio by purchasing 1,911 company shares during the most recent quarter which is valued at $215,446. Johnson & Johnson makes up approx 0.13% of Arkansas Financial Group’s portfolio.Parsec Financial Management reduced its stake in JNJ by selling 46 shares or 0.03% in the most recent quarter. The Hedge Fund company now holds 159,748 shares of JNJ which is valued at $17.9 Million. Johnson & Johnson makes up approx 1.77% of Parsec Financial Management’s portfolio.
Johnson & Johnson opened for trading at $113.39 and hit $114.63 on the upside on Monday, eventually ending the session at $114.44, with a gain of 0.77% or 0.88 points. The heightened volatility saw the trading volume jump to 62,22,861 shares. Company has a market cap of $314,784 M.
On the company’s financial health, Johnson & Johnson reported $1.68 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Apr 19, 2016. Analyst had a consensus of $1.65. The company had revenue of $17482.00 million for the quarter, compared to analysts expectations of $17491.02 million. The company’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.56 EPS.
Investors should note that on Apr 28, 2016, Johnson & Johnson announced a cash dividend of $0.8000. The company’s management has announced May 20, 2016 as the ex-dividend date and fixed the record date on May 24, 2016. The payable date has been fixed on Jun 7, 2016.
Many Wall Street Analysts have commented on Johnson & Johnson. Company shares were Reiterated by RBC Capital Mkts on Apr 20, 2016 to “Outperform”, Firm has raised the Price Target to $ 125 from a previous price target of $122 .Company shares were Reiterated by Piper Jaffray on Apr 20, 2016 to “Neutral”, Firm has raised the Price Target to $ 106 from a previous price target of $105 .Company shares were Reiterated by RBC Capital Mkts on Apr 15, 2016 to “Outperform”, Firm has raised the Price Target to $ 122 from a previous price target of $114 .
Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Companys primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Companys research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.